ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2002, p. 2708–2711 0066-4804/02/$04.00⫹0 DOI: 10.1128/AC.46.8.2708–2711.2002 Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Vol. 46, No. 8
In Vitro Susceptibilities of Zygomycetes to Combinations of Antimicrobial Agents Eric Dannaoui,1 Javier Afeltra,1 Jacques F. G. M. Meis,2 Paul E. Verweij,1* and The Eurofung Network† Department of Medical Microbiology, University Medical Center St. Radboud, 6500 HB Nijmegen,1 and Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital, 65000 GS Nijmegen,2 The Netherlands Received 16 January 2002/Returned for modification 14 February 2002/Accepted 30 April 2002
Combinations of antimicrobial agents were tested against 35 strains of zygomycetes. The interaction between amphotericin B and rifampin was synergistic or additive. Flucytosine alone was inactive and, upon combination with amphotericin B, synergy was not achieved. The combination of amphotericin B with terbinafine was synergistic for 20% of strains, and the interaction between terbinafine and voriconazole was synergistic for 44% of strains. Antagonism was not observed. zygomycosis (12, 31). Synergy between terbinafine and azoles has also been demonstrated in yeasts (2, 3, 15) and in filamentous fungi (28, 38, 43). The combination of terbinafine with voriconazole has rarely been investigated (38, 43). The aim of this study was to investigate the in vitro interactions of amphotericin B with rifampin, flucytosine, and terbinafine as well as the interaction of terbinafine with voriconazole against zygomycetes. A total of 35 isolates were tested. These comprised 15 Rhizopus spp. (8 R. oryzae and 7 R. microsporus) isolates, 10 Absidia corymbifera isolates, 6 Mucor spp. (3 M. hiemalis, 1 M. circinelloides, 1 M. racemosus, and 1 M. rouxii) isolates, 3 Rhizomucor spp. (2 R. pusillus and 1 R. miehei) isolates, and 1 Cunninghamella bertholletiae isolate. Candida krusei ATCC 6258 and Candida parapsilosis ATCC 22019 were included to ensure quality control. The drugs that were tested included voriconazole (Pfizer Central Research, Sandwich, United Kingdom), terbinafine (Novartis Pharma, Basel, Switzerland), flucytosine (ICN Pharmaceuticals, Zoetermeer, The Netherlands), amphotericin B (Bristol-Myers Squibb, Woerden, The Netherlands), and rifampin (Sigma-Aldrich Chemie GmbH, Steinheim, Germany). For the combination of terbinafine with either voriconazole or amphotericin B, a checkerboard with twofold dilutions of each drug was used. The final concentrations were 0.03 to 2 g/ml for amphotericin B, 0.5 to 32 g/ml for voriconazole, and either 0.004 to 2 g/ml or 0.25 to 128 g/ml for terbinafine, depending on the susceptibilities of the tested isolates. For the combination of amphotericin B with either rifampin or flucytosine, a limited checkerboard with twofold dilutions of amphotericin B and fourfold dilutions of the other drug was used. The final concentrations were 0.008 to 4 g/ml for amphotericin B, 0.25 to 16 g/ml for rifampin, and 8 to 128 g/ml for flucytosine. Drug combinations were tested using the guidelines of the National Committee for Clinical Laboratory Standards (NCCLS) proposed standard M38-P (29) modified for a broth microdilution checkerboard procedure. Spore suspensions were counted with a hemacytometer and then diluted into RPMI to a concentration of 2 ⫻ 104 spores/ml (2⫻ final concentration). Microplates were incubated at 37°C, and MICs
Zygomycosis is an aggressive infection occurring mostly in patients with diabetic ketoacidosis or neutropenia or in patients receiving corticosteroids (35). Despite antifungal therapy, mortality remains very high, particularly in the pulmonary and disseminated forms of the disease (21, 26, 42). Amphotericin B is the drug of choice for treatment, but its use is limited by its narrow therapeutic index (14). Few studies have been carried out to test antifungal combinations against zygomycetes in vitro (5, 41) or in animal models of zygomycosis (40). Combination of amphotericin B with rifampin has proven to be synergistic in vitro against yeasts (4, 8, 13, 27), dimorphic fungi (25, 36), Aspergillus (19, 24), and Rhizopus (5). Nevertheless, in animal models of fungal infections, results for this combination have been conflicting (10, 16). Interaction between amphotericin B and flucytosine has been shown to be additive or synergistic against yeasts in vitro and in vivo in animal models as well as in patients (34). With Aspergillus, indifferent-to-synergistic and in some instances antagonistic interactions have been reported for this combination (7, 19). Terbinafine is a sterol biosynthesis inhibitor that is primarily used for superficial mycoses, but its current applications are extending (33). Although the potential of this antifungal for zygomycosis is unknown, terbinafine exhibits low MICs against some zygomycete isolates (22). Combination of amphotericin B with terbinafine displayed synergistic interaction in Candida albicans (2) and in Aspergillus spp. (38), and this combination has been used successfully in patients for the treatment of aspergillosis (39) and
* Corresponding author. Mailing address: Department of Medical Microbiology, University Medical Center Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. Phone: (31) 24 361 43 56. Fax: (31) 24 354 02 16. E-mail:
[email protected]. † The Eurofung Network consists of the following participants: Emmanuel Roilides, coordinator, and Nicos Maglaveras, Aristotle University, Thessaloniki, Greece; Tore Abrahamsen and Peter Gaustad, Rikshospitalet National Hospital, Oslo, Norway; David W. Denning, University of Manchester, Manchester, United Kingdom; Paul E. Verweij and Jacques F. G. M. Meis, University of Nijmegen, Nijmegen, The Netherlands; Juan L. Rodriguez-Tudela, Instituto de Salud Carlos III, Madrid, Spain; and George Petrikkos, Athens University, Athens, Greece. 2708
VOL. 46, 2002
NOTES
2709
TABLE 1. Summary of drug interaction for the four combinations tested % of isolates showing synergism, additivity, and antagonism for the combinationa: AMB and RIF
Genera (no. of strains)
Rhizopus spp. (15) Absidia spp. (10) Other (10) All isolates (35)
AMB and 5FC
TER and AMB
TER and VRZ
Syn
Add
Ant
Syn
Add
Ant
Syn
Add
Ant
Syn
Add
Ant
40 100 80 69
60 0 20 31
0 0 0 0
0 0 0 0
100 100 100 100
0 0 0 0
27 10 20 20
73 90 80 80
0 0 0 0
60 0 67 44
40 100 33 56
0 0 0 0
a AMB, amphotericin B; RIF, rifampin; 5FC, 5-fluorocytosine; TER, terbinafine; VRZ, voriconazole. Syn, synergism (FIC index ⱕ 0.5); Add, additivity or indifference (FIC index ⬎ 0.5 and ⱕ 4); Ant, antagonism (FIC index ⬎ 4).
were determined visually after 24 h of incubation. MIC determinations were done in duplicate, and results were within 1 log2 dilution in 90% of the cases. Each well was given a numerical score from 4 (no reduction in growth) to 0 (absence of growth) according to the NCCLS guidelines (29). For the combination of amphotericin B with rifampin or flucytosine, MIC endpoints were defined as the lowest drug concentration (tested alone or in combination) which had a score of 0 (MIC-0). For the combination of terbinafine with voriconazole, MIC-2 was used as the endpoint for both drugs, alone or in combination. For the combination of terbinafine with amphotericin B, MIC-0 was used for amphotericin B alone and MIC-2 was used for terbinafine alone and for both drugs in combination. The fractional inhibitory concentrations (FICs) of both drugs used in combination were calculated and added to obtain the FIC indices (9). Drug interactions were defined as synergistic if the FIC index was ⱕ0.5, as additive if the FIC index was ⬎0.5 and ⱕ1, indifferent if the FIC index was ⬎1 and ⱕ4, and antagonistic if the FIC index was ⬎4. The number of strains showing synergy within the different genera were compared by using Fisher’s exact test. The geometric mean MIC and the MIC at which 90% of isolates were inhibited (MIC90) of amphotericin B were 0.24 and 1 g/ml, respectively. Only one strain (C. bertholletiae) showed a high amphotericin B MIC of 2 g/ml. Growth of all isolates was not inhibited by rifampin (MIC ⬎ 16 g/ml), with the exception of two Rhizomucor spp. isolates that exhibited a MIC of 16 g/ml. The interaction between amphotericin B and rifampin was synergistic in 69% of the cases and additive in 31% of the cases. Indifference and antagonism were not observed (highest FIC indices ranged from 0.5 to 2.02). For the synergistic interactions, the median concentration of amphotericin B in combination was 0.03 g/ml (range, 0.008 to 0.25 g/ml), and the median concentration of rifampin in combination was 4 g/ml (range, 1 to 16 g/ml). Synergism was observed for all the A. corymbifera isolates (P ⬍ 0.0028 compared with Rhizopus spp.), for 40% of the Rhizopus spp. isolates, and for most of the other species (Table 1). Flucytosine alone was inactive against all the isolates (MIC ⬎ 128 g/ml). Upon combination, synergy was not achieved. Additivity or indifference was observed for all the strains. Antagonism was not observed. Terbinafine MICs ranged from 0.015 to ⬎128 g/ml. The highest MICs of terbinafine were observed against R. oryzae and Mucor spp. For the combination between terbinafine and amphotericin B, synergistic interactions were observed for 20% of the strains and additive or
indifferent interactions were noted for 80% of the strains. There were no antagonistic interactions. For the synergistic interactions, the median concentration of amphotericin B in combination was 0.125 g/ml (range, 0.03 to 0.5 g/ml) and the median concentration of terbinafine in combination was 0.25 g/ml (range, 0.015 to 8 g/ml). The percentage of isolates showing synergism was not significantly different between species (Table 1). The geometric mean MIC and the MIC90 of voriconazole were 7.8 and 32 g/ml, respectively. The interaction between terbinafine and voriconazole was synergistic for 44% of the strains and additive or indifferent for 56% of the strains. Antagonism was not observed. For the synergistic interactions the median concentration of terbinafine in combination was 0.5 g/ml (range, 0.015 to 16 g/ml) and the median concentration of voriconazole in combination was 1 g/ml (range, 0.5 to 8 g/ml). Synergism was detected for 60% of the Rhizopus spp. isolates (Table 1). In contrast, no synergistic interaction was observed for A. corymbifera (P ⬍ 0.0028 compared with Rhizopus spp.; P ⬍ 0.0031 compared with other species). Zygomycosis remains a very severe infection. The overall mortality of localized pulmonary zygomycosis is 65% (42), and it is ⬎95% in disseminated forms of the disease (21, 42). Combination therapy is commonly used for difficult-to-treat bacterial and some fungal infections and could be a useful strategy in zygomycosis. In patients with zygomycosis, combination therapy with amphotericin B and rifampin (5, 6, 30) or amphotericin B and terbinafine (12, 31) has been reported. Nevertheless, it is not possible to draw conclusions from these anecdoctal case reports. Few studies have been done to evaluate the potential of drug combinations against zygomycetes (5, 40, 41). In vitro data are limited to a study showing synergism between amphotericin B and rifampin in Rhizopus spp. (5). In a murine model of pulmonary mucormycosis due to R. oryzae, it was shown that combination of fluconazole with quinolones was effective (40). It has to be pointed out that positive interaction between these drugs was not demonstrated in vitro (41). In the present study, we found synergistic interactions between amphotericin B and rifampin at clinically relevant concentrations of rifampin (32). Interestingly, there was a clear difference between different genera; a synergistic interaction was obtained for all the A. corymbifera strains compared to 40% of the Rhizopus spp. strains. Although different susceptibility testing methods and different definitions of synergism have been used, in vitro synergistic interaction has been usually documented for yeasts (4, 8, 13, 27, 37). For hyphomycetes,
2710
NOTES
ANTIMICROB. AGENTS CHEMOTHER.
synergistic interactions were found in Aspergillus spp. (7, 19, 24) but not in Fusarium spp. (17). It has also been shown that rifampin acts synergistically with amphotericin B against dimorphic fungi in vitro (20, 25, 36). Nevertheless, in animal models results have been conflicting. Although potentiation of amphotericin B by rifampin has been demonstrated for the treatment of murine aspergillosis (1) or histoplasmosis and blastomycosis (23), the combination was not beneficial in the treatment of disseminated candidiasis in mice (10, 16). One reason for discrepancies between in vitro and in vivo results may be that FIC indices that are only just below 0.5 may not really be indicating very strong synergy. As zygomycosis remains a very difficult to treat infection, it is probably of interest to test this combination in animal models, particularly for Absidia infections. We found synergistic interactions between amphotericin B and terbinafine for 20% of the strains, with a median concentration of terbinafine in combination of 0.25 g/ml, which is within the range achievable in serum (11). In vitro studies have shown synergistic interactions between amphotericin B and terbinafine against C. albicans (2) and Aspergillus spp. (38). Moreover, this combination has been used in patients with zygomycosis (12, 31) and aspergillosis (39). Although combination between azoles and amphotericin B is considered potentially antagonistic, it is to be noticed that no antagonism was observed between terbinafine (an ergosterol biosynthesis inhibitor) and amphotericin B in the present study. Although the first-line therapy for zygomycosis remains parenteral amphotericin B, we have tested the combination of voriconazole with terbinafine and found synergistic interaction between these two drugs in 44% of isolates. There was a significant difference between genera; synergism was not observed for A. corymbifera but was demonstrated for 60% of the Rhizopus spp. strains. Moreover, the median concentration of voriconazole in combination was 1 g/ml, which is within the range achievable in serum (18). In vitro synergism has been demonstrated for the combination of terbinafine with either fluconazole or itraconazole against C. albicans (2, 3), Scedosporium prolificans (28), and Aspergillus spp. (38), and these combinations have also been used in humans. Few studies have tested the interaction of terbinafine with voriconazole. In two recent studies it has been shown that terbinafine in combination with voriconazole displayed potent synergies against C. albicans (43) and Aspergillus spp. (38). In summary, the results of this study demonstrated that some antifungal combinations are synergistic in vitro against zygomycetes, with different results for Rhizopus spp. and A. corymbifera. Further studies in animal models of zygomycosis are necessary to confirm the clinical potential of these combinations. This work was supported by a European Community grant (TMREurofung Network, contract ERBFMRXCT97-0145) and by the Mycology Research Center, Nijmegen, The Netherlands.
3.
4. 5. 6. 7. 8. 9. 10.
11. 12. 13. 14. 15. 16. 17. 18. 19.
20.
21. 22. 23. 24. 25. 26. 27.
REFERENCES 1. Arroyo, J., G. Medoff, and G. S. Kobayashi. 1977. Therapy of murine aspergillosis with amphotericin B in combination with rifampin or 5-fluorocytosine. Antimicrob. Agents Chemother. 11:21–25. 2. Barchiesi, F., L. F. Di Francesco, P. Compagnucci, D. Arzeni, A. Giacometti, and G. Scalise. 1998. In-vitro interaction of terbinafine with amphotericin B,
28.
29.
fluconazole and itraconazole against clinical isolates of Candida albicans. J. Antimicrob. Chemother. 41:59–65. Barchiesi, F., L. Falconi Di Francesco, and G. Scalise. 1997. In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. Antimicrob. Agents Chemother. 41:1812–1814. Beggs, W. H., G. A. Sarosi, and M. I. Walker. 1976. Synergistic action of amphotericin B and rifampin against Candida species. J. Infect. Dis. 133: 206–209. Christenson, J. C., I. Shalit, D. F. Welch, A. Guruswamy, and M. I. Marks. 1987. Synergistic action of amphotericin B and rifampin against Rhizopus species. Antimicrob. Agents Chemother. 31:1775–1778. Craig, N. M., F. L. Lueder, J. M. Pensler, B. S. Bean, M. L. Petrick, R. B. Thompson, and L. R. Eramo. 1994. Disseminated Rhizopus infection in a premature infant. Pediatr. Dermatol. 11:346–350. Denning, D. W., L. H. Hanson, A. M. Perlman, and D. A. Stevens. 1992. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn. Microbiol. Infect. Dis. 15:21–34. Edwards, J. E., Jr., J. Morrison, D. K. Henderson, and J. Z. Montgomerie. 1980. Combined effect of amphotericin B and rifampin on Candida species. Antimicrob. Agents Chemother. 17:484–487. Eliopoulos, G. M., and R. C. Moellering. 1991. Antimicrobial combinations, p. 432–492. In V. Lorian (ed.), Antibiotics in laboratory medicine. The Williams & Wilkins Co., Baltimore, Md. Ernst, J. D., M. Rusnak, and M. A. Sande. 1983. Combination antifungal chemotherapy for experimental disseminated candidiasis: lack of correlation between in vitro and in vivo observations with amphotericin B and rifampin. Rev. Infect. Dis. 5(Suppl. 3):S626–S630. Faergemann, J. 1997. Pharmacokinetics of terbinafine. Rev. Contemp. Pharmacother. 8:289–298. Foss, N. T., M. R. Rocha, V. T. Lima, M. A. Velludo, and A. M. Roselino. 1996. Entomophthoramycosis: therapeutic success by using amphotericin B and terbinafine. Dermatology 193:258–260. Fujita, N. K., and J. E. Edwards, Jr. 1981. Combined in vitro effect of amphotericin B and rifampin on Cryptococcus neoformans. Antimicrob. Agents Chemother. 19:196–198. Georgopapadakou, N. H., and T. J. Walsh. 1994. Human mycoses: drugs and targets for emerging pathogens. Science 264:371–373. Ghannoum, M. A., and B. Elewski. 1999. Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine. Clin. Diagn. Lab. Immunol. 6:921–923. Graybill, J. R., and J. Ahrens. 1983. Interaction of rifampin with other antifungal agents in experimental murine candidiasis. Rev. Infect. Dis. 5(Suppl. 3):S620–S625. Guarro, J., I. Pujol, and E. Mayayo. 1999. In vitro and in vivo experimental activities of antifungal agents against Fusarium solani. Antimicrob. Agents Chemother. 43:1256–1257. Hoffman, H. L., E. J. Ernst, and M. E. Klepser. 2000. Novel triazole antifungal agents. Expert Opin. Investig. Drugs 9:593–605. Hughes, C. E., C. Harris, J. A. Moody, L. R. Peterson, and D. N. Gerding. 1984. In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp. Antimicrob. Agents Chemother. 25:560–562. Huppert, M., D. Pappagianis, S. H. Sun, I. Gleason-Jordan, M. S. Collins, and K. R. Vukovich. 1976. Effect of amphotericin B and rifampin against Coccidioides immitis in vitro and in vivo. Antimicrob. Agents Chemother. 9:406–413. Ingram, C. W., J. Sennesh, J. N. Cooper, and J. R. Perfect. 1989. Disseminated zygomycosis: report of four cases and review. Rev. Infect. Dis. 11:741– 754. Jessup, C. J., N. S. Ryder, and M. A. Ghannoum. 2000. An evaluation of the in vitro activity of terbinafine. Med. Mycol. 38:155–159. Kitahara, M., G. S. Kobayashi, and G. Medoff. 1976. Enhanced efficacy of amphotericin B and rifampicin combined in treatment of murine histoplasmosis and blastomycosis. J. Infect. Dis. 133:663–668. Kitahara, M., V. K. Seth, G. Medoff, and G. S. Kobayashi. 1976. Activity of amphotericin B, 5-fluorocytosine, and rifampin against six clinical isolates of Aspergillus. Antimicrob. Agents Chemother. 9:915–919. Kobayashi, G. S., G. Medoff, D. Schlessinger, C. N. Kwan, and W. E. Musser. 1972. Amphotericin B potentiation of rifampicin as an antifungal agent against the yeast phase of Histoplasma capsulatum. Science 177:709–710. Lee, F. Y., S. B. Mossad, and K. A. Adal. 1999. Pulmonary mucormycosis: the last 30 years. Arch. Intern. Med. 159:1301–1309. Medoff, G., G. S. Kobayashi, C. N. Kwan, D. Schlessinger, and P. Venkov. 1972. Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell synergism). Proc. Natl. Acad. Sci. USA 69:196–199. Meletiadis, J., J. W. Mouton, J. L. Rodriguez-Tudela, J. F. Meis, and P. E. Verweij. 2000. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob. Agents Chemother. 44:470–472. National Committee for Clinical Laboratory Standards. 1998. Reference
VOL. 46, 2002
30. 31. 32. 33. 34. 35. 36.
method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed standard M38-P. National Committee for Clinical Laboratory Standards, Wayne, Pa. Ng, T. T., C. K. Campbell, M. Rothera, J. B. Houghton, D. Hughes, and D. W. Denning. 1994. Successful treatment of sinusitis caused by Cunninghamella bertholletiae. Clin. Infect. Dis. 19:313–316. Norden, G., S. Bjorck, H. Persson, C. Svalander, X. G. Li, and L. Edebo. 1991. Cure of zygomycosis caused by a lipase-producing Rhizopus rhizopodiformis strain in a renal transplant patient. Scand. J. Infect. Dis. 23:377–382. Peloquin, C. A., G. S. Jaresko, C. L. Yong, A. C. Keung, A. E. Bulpitt, and R. W. Jelliffe. 1997. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob. Agents Chemother. 41:2670–2679. Perez, A. 1999. Terbinafine: broad new spectrum of indications in several subcutaneous and systemic and parasitic diseases. Mycoses 42(Suppl. 2):111– 114. Polak, A. 1999. The past, present and future of antimycotic combination therapy. Mycoses 42:355–370. Ribes, J. A., C. L. Vanover-Sams, and D. J. Baker. 2000. Zygomycetes in human disease. Clin. Microbiol. Rev. 13:236–301. Rifkind, D., E. D. Crowder, and R. N. Hyland. 1974. In vitro inhibition of Coccidioides immitis strains with amphotericin B plus rifampin. Antimicrob. Agents Chemother. 6:783–784.
NOTES
2711
37. Rodero, L., S. Cordoba, P. Cahn, F. Hochenfellner, G. Davel, C. Canteros, S. Kaufman, and L. Guelfand. 2000. In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy. J. Antimicrob. Chemother. 45:239–242. 38. Ryder, N. S., and I. Leitner. 2001. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med. Mycol. 39:91– 95. 39. Schiraldi, G. F., and M. D. Colombo. 1997. Potential use of terbinafine in the treatment of aspergillosis. Rev. Contemp. Pharmacother. 8:349–356. 40. Sugar, A. M., and X. P. Liu. 2000. Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles. Antimicrob. Agents Chemother. 44:2004–2006. 41. Sugar, A. M., X. P. Liu, and R. J. Chen. 1997. Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugs. Antimicrob. Agents Chemother. 41:2518–2521. 42. Tedder, M., J. A. Spratt, M. P. Anstadt, S. S. Hegde, S. D. Tedder, and J. E. Lowe. 1994. Pulmonary mucormycosis: results of medical and surgical therapy. Ann. Thorac. Surg. 57:1044–1050. 43. Weig, M., and F. M. Muller. 2001. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. 45:966–968.
